Variability in response to aspirin: Do we understand the clinical relevance?

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 4, 2005, Pages 665-669

  Campbell, C L ^a   Steinhubl, S R ^b   Campbell, Charles L ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CYCLOOXYGENASE 2 INHIBITOR; EPTIFIBATIDE; HEPARIN; PADGEM PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE A2; THROMBOXANE B2; TICLOPIDINE; TIROFIBAN; ANTITHROMBOCYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

BLEEDING TIME; BLOOD VESSEL OCCLUSION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; DRUG FATALITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TOLERANCE; ENZYME INHIBITION; EX VIVO STUDY; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; STROKE; SYSTEMATIC REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT FAILURE; UNSTABLE ANGINA PECTORIS; ACUTE DISEASE; CORONARY ARTERY DISEASE; DRUG RESISTANCE; TIME; TREATMENT OUTCOME;

ACUTE DISEASE; ANGINA, UNSTABLE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CLINICAL TRIALS; CORONARY DISEASE; DRUG RESISTANCE; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 23044435873     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01119.x     Document Type: Review

References (52)

1. Feldman M, Cryer B. Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. Am J Cardiol 1999; 84: 404-9.
2. Awtry E, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-18.
3. Burch J, Stanford N, Majerus P. Inhibition of platelet prostaglandin synthase by oral aspirin. J Clin Invest 1979; 61: 314-19.
4. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Davi G, Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985; 72: 177-84.
5. Bradlow BA, Chetty N. Dosage frequency for suppression of platelet function by low dose aspirin therapy. Thromb Res 1982; 27: 99-110.
6. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Ann Rev Pharmacol Toxicol 1998; 38: 97-120.
7. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 353: 900.
8. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, Schror K, Hohlfeld T. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-7.
9. Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 246-55.
10. Chandrasekharan N, Dai H, Roos K, Evanson NK, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc Natl Acad Sci USA 2002; 99: 13926-1.
11. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988; 2: 349-60.
12. Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE III, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, De Mots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396-403.
13. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
14. Col NF, Yarzbski J, Gore JM, Alpert JS, Goldberg RJ. Does aspirin consumption affect the presentation or severity of acute myocardial infarction? Arch Intern Med 1995; 155: 1386-9.
15. Garcia-Dorado D, Theroux P, Tornos P, Sambola A, Oliveras J, Santos M, Soler J. Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes. Circulation 1995; 92: 1743-8.
16. Ridker PM, Manson JE, Buring JE, Goldhaber SZ, Hennekens CH. Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy. Circulation 1991; 84: 708-11.
17. Lancaster G, Lancaster C, Barr E, Radley D, Fromell G, Cohen M. Prior aspirin use in unstable coronary syndromes results in a lower incidence of non-Q-wave MI but a higher rate of medical therapy failure with unfractionated heparin: the aspirin paradox [Abstract]. Circulation 1999; 100 (Suppl. I): I-620.
18. Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980; 243: 661-9.
19. Cleland JGF. Preventing atherosclerotic events with aspirin. BMJ 2002; 325: 103-5.
20. Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, Simoons ML, Guerci A, Hochman JS, Wilcox RG, Kitt MM, Eisenberg PR, Califf RM, Topol EJ, Karsh K, Ruzyllo W, Stepinska J, Widimsky P, Boland JB, Armstrong PW. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. Am J Cardiol 1999; 83: 1147-51.
21. Santopinto J, Gurfinkel E, Torres V, Marcos E, Bozovich G, Mautner B, McCabe CH, Antman EM. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. Am Heart J 2001; 141: 566-72.
22. Cohen M, Demers C, Gurfinkel E, Turpie AGG, Fromell G, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-52.
23. Antman E, Cohen M, Bernink P, McCabe C, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI. A method of prognostication and therapeutic decision making. JAMA 2000; 284: 835-42.
24. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition with the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
25. Bhatt DL. Aspirin resistance: more than just a laboratory curiosity. JACC 2004; 43: 1127-9.
26. Hurlen M, Seljeflot I, Arnesen H. Platelet aggregability after myocardial infarction. Evidence of aspirin non-responsiveness in a subpopulation [abstract]. Eur Heart J 1996; 17: 262.
27. Benedek IH, Joshi AS, Pieniaszek HJ, King S-YP, Kornhauser DM. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 1995; 35: 1181-6.
28. Pappas JM, Westengard JC, Bull BS. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Laboratory Med 1994; 118: 801-4.
29. Poggio ED, Kottke-Marchant K, Welsh PA, Brooks LM, Dela Rosa LR, Topol EJ. The prevalence of aspirin resistance in cardiac patients as measured by platelet aggregation and PFA-100 [Abstract]. J Am Coll Cardiol 1999; 33(Suppl. A): 254A.
30. Valettas N, Morgan CD, Reis M. Aspirin resistance using flow cytometry [Abstract]. Blood 1997; 10(Suppl. 1): 124b.
31. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically. Can J Cardiol 1995; 11: 221-7.
32. Steinhubl S, Talley J, Braden G, Tcheng J, Casterella P, Moliterno D, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event following percutaneous coronary intervention. Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103 (21): 2572-8.
33. Gum PA, Kottke-Marchant K, Poggio ED, Gum H, Welsh PA, Brooks LM, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-5.
34. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-5.
35. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin nonresponsiveness as measured by PFA 100 in patients with coronary artery disease. Thromb Res 2003; 108: 37-42.
36. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331-6.
37. Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004; 43(6): 979-84.
38. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Eng J Med 2002; 347: 1309-17.
39. Zimmerman C, Kienzle P, Weber AA, Winter J, Gams E, Schror K, Hohlfeld T. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 121: 982-4.
40. Patrono C. Aspirin resistance: definition, mechanisms and clinical read outs. J Thromb Haemost 2003; 1: 1710-13.
41. Grotemeyer K-H, Scharafinski H-W, Husstedt I-W. Two-year follow-up of aspirin responder and aspirin non-responder. A pilot study including 180 post-stroke patients. Throm Res 1993; 71: 397-403.
42. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, Koppensteiner R, Ergun E, Mittlboeck M, Schreiner W, Losert U, Wolner E. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients, submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-7.
43. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
44. Topol EJ. Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease - authors reply. J Am Coll Cardiol 2003; 42: 1336-7.
45. Chakroun T, Gerotziafas G, Robert F, Lecrubier C, Samama M, Hatmi M, Elalamy I. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 2004; 124: 80-5.
46. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous intervention despite clopidogrel treatment. J Am Coll Cardiol 2004; 43: 1122-6.
47. Alexander JH, Steinhubl SR. Aspirin Resistance. In: Topol, EJ, ed. Acute Coronary Syndromes. Marcel Dekker: New York. 2001; 499-514.
48. Cambria-Kiely JA, Gandhi P. Aspirin resistance and genetic polymorphisms. J Thromb Haemost 2002; 14: 51-8.
49. Patrignani P. Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res 2003; 110: 281-6.
50. Cambria-Kiely JA, Gandhi P. Possible mechanisms of aspirin resistance. J Thromb Thrombolysis 2002; 13: 49-56.
51. Singh S, Kothari S, Bahl V. Aspirin resistance: myth or reality. Indian Heart J 2003; 55: 217-22.
52. Valles J, Santos MT, Aznar J, Osa A, Lago A, Cosin J, Sanchez E, Broekman MJ, Marcus AJ. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality. The effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998; 97: 350-5.